The Impact of Pazopanib on the Cardiovascular System

Cody N. Justice, Mohamed H. Derbala, Tesla M. Baich, Amber N. Kempton, Aaron S. Guo, Thai H. Ho, Sakima A. Smith

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma. However, its clinical efficacy is limited by its cardiovascular side effects. Pazopanib and other vascular endothelial growth factor receptor tyrosine kinase inhibitors have been associated with the development of hypertension, QT interval prolongation, and other cardiovascular events; however, these mechanisms are largely unknown. Gaining a deeper understanding of these mechanisms is essential for the development of appropriate surveillance strategies and possible diagnostic biomarkers to allow us to monitor patients and modulate therapy prior to significant cardiac insult. This approach will be vital in keeping patients on these life-saving therapies and may be applicable to other tyrosine kinase inhibitors as well. In this review, we provide a comprehensive overview of the preclinical and clinical side effects of pazopanib with a focus on the mechanisms responsible for its toxicity to the cardiovascular system.

Original languageEnglish (US)
Pages (from-to)387-398
Number of pages12
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume23
Issue number5
DOIs
StatePublished - Sep 1 2018

Keywords

  • hypertension
  • pazopanib
  • renal cell carcinoma
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The Impact of Pazopanib on the Cardiovascular System'. Together they form a unique fingerprint.

  • Cite this

    Justice, C. N., Derbala, M. H., Baich, T. M., Kempton, A. N., Guo, A. S., Ho, T. H., & Smith, S. A. (2018). The Impact of Pazopanib on the Cardiovascular System. Journal of Cardiovascular Pharmacology and Therapeutics, 23(5), 387-398. https://doi.org/10.1177/1074248418769612